Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07415031 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 100 to 102
  2. Study sites revised (100) Eligibility criteria expanded, about 5 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 5 words
  3. Study sites: 101 to 100v6
  4. Study sites: 100 to 101v5
  5. Trial sites expanded: 77 → 100 locationsv4
  6. Recruitment opened Trial sites expanded: 30 → 77 locations · Start date changed from estimate of May 16, 2026 to May 6, 2026v3 Show 2 more changesShow less
    • Trial sites expanded: 30 → 77 locations
    • Start date changed from estimate of May 16, 2026 to May 6, 2026
  7. Trial sites expanded: 0 → 30 locationsv2
  8. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.
Trial Details
NCT Number NCT07415031
Lead Sponsor Mirati Therapeutics Inc.
Conditions Solid Tumors
Enrollment 170 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov